IT Idursulfase Trial Faces Setback

Please read:

https://endpts.com/shire-hit-by-a-setback-as-hunter-syndrome-drug-fails-late-stage-study/

https://www.shire.com/en/newsroom/2017/december/wvdwq3

I’m not going to say a lot right now as I’m still processing this news and I’m not sure how much I can/should/want to be posting on the big wide web. What I do know without a doubt is that this drug works and I will go to jail before I see this drug get taken away. Melissa Hogan has issued a Clinical Trial Alert that contains more information, please see below.

ClinicalTrialAlert-SHP609

If you have questions, don’t hesitate to reach out.

Love Deb

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • del.icio.us
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks

2 thoughts on “IT Idursulfase Trial Faces Setback

  1. “Two out of three patients exhibit progressive cognitive decline.”
    But this did not happen with 1/3 of the patients! That is huge!
    This disease is slightly different in everyone. Why not look into the patients that Elaprase DID work for – and try to determine the characteristics which make this viable for those patients. You CAN make a difference for those patients. Please.

    Branch 2: go back to the 2/3 patients that it didn’t work for and try to reformulate a medication for those types of patients.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.